Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

British Journal of Cancer

Volumn 85, Issue 5, 2001, Pages 649-655

  Pivot, X ^a   Raymond, E ^b   Laguerre, B ^c   Degardin, M ^d   Cals, L ^e   Armand, J P ^b   Lefebvre, J L ^d   Gedouin, D ^c   Ripoche, V ^f   Kayitalire, L ^f   Niyikiza, C ^f   Johnson, R ^f   Latz, J ^g   Schneider, M ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d Center Oscar Lambret   (France)

^e Hopital Font Pré   (France)

^f ELI LILLY AND COMPANY   (United States)

^g NONE

Author keywords

ALIMTA ; Chemotherapy; Head and neck squamous cell carcinoma; LY231514; Multitargeted antifolate; Pemetrexed disodium

Indexed keywords

DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; ENZYME INHIBITORS; FEMALE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; REMISSION INDUCTION; THROMBOCYTOPENIA;

EID: 0035446433     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2010     Document Type: Article

References (28)

1. Augmentation of the therapeutic activity of lometrexol -(6-R) 5,10-dideazatetrahydrofolate- by oral folic acid
2. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck
3. Vitamin B12 and Folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite
4. Clinical studies with MTA
5. Cellular pharmacology of MTA: A correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
6. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group
7. Overview of combined modality therapies for head and neck cancer
8. AJJC cancer staging manual. 5th ed.
9. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
10. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group study
11. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study
12. Cancer statistics, 1999
13. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects
14. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol
15. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
16. MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity
17. Overview of phase II trials of MTA in solid tumors
18. Overview of MTA in the treatment of non-small cell lung cancer
19. Multivariate analysis of prognostic factors in local recurrent and metastatic head and neck cancer: Implication for clinical trials
20. Recurrent and/or metastatic head and neck squamous cell carcinoma: A clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy
21. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
22. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
23. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study
24. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
25. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid
26. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer
27. Head and neck cancer